Guideline for Bioequivalence Studies of Controlled Release Products |
Seo, Hyun-Ok
(Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration)
Kim, So-Hee (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Ahn, Mee-Ryung (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Ahn, Choong-Yul (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Park, Hye-Jin (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Oh, Eun-Kyung (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Lee, Eun-Ju (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Kim, Bo-Yeon (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Kim, Min-Jeong (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Woo, Na-Ry (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Seo, Hee-Won (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) Chung, Soo-Youn (Bioequivalence Evaluation Division, Drug Evaluation Department, Pharmaceutical Safety Bureau, Korea Food and Drug Administration) |
1 | Guidance Document for Bioequivalence Study(KFDA Notification #2009-184), KFDA, Korea (2009). |
2 | Note for Guidance on the Investigation of Bioavailability and Bioequivalence, EMEA (2001). |
3 | Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part B: Oral Modified Release Formulations, Health Canada, Canada (1996). |
4 | Regulation on Drug Product Authorization, Declaration, & Review (KFDA Notification #2009-209), KFDA, Korea (2009). |
5 | Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies, FDA, US (2002). |
6 | L. Hendeles, M. Weinberger, G. Milavetz and M. Hill, Food-Induced “Dose-Dumping” from a Once-a-Day Theophylline Product as a Cause of Theophylline Toxicity, Chest, 87(6), 758-765 (1985). DOI |
7 | Guideline on Food-Effect Bioavailability and Fed Bioequivalence Studies, NITR, Korea (2005). |
8 | Guideline for Bioequivalence Studies of Generic Products, Ministry of Health, Labour and Welfare, Japan (2006). |
9 | J.M. Custodio, C.Y. Wu and L.Z. Benet, Predicting Drug Disposition, Absorption/Elimination/Transporter Interplay and the Role of Food on Drug Absorption, Advanced Drug Deilivery Reviews, 60, 717-733 (2008) DOI |
10 | Guidnace for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, FDA, US (2003). |
11 | Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section (Pharmacokinetic and Clinical Evaluation), EMEA (1999). |
12 | Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part A: Oral Dosage Formulations Used for Systemic Effects, Health Canada, Canada (1992). |
13 | Multisource (generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability, WHO Technical Report Series, No. 937, 347-390 (2006). |